GSK’s ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment
Shots:
- ViiV Healthcare (owned by GSK with Pfizer & Shionogi as shareholders) has received the CHMP's positive opinion for Vocabria (cabotegravir) combined with J&J’s Rekambys (rilpivirine) to treat HIV-1 in virologically suppressed adolescents (≥12yrs. & ≥35kg), with the decision expected soon. It has been approved for adults in Dec 2020
- Recommendation was based on 24wks. P-I/II (MOCHA) trial evaluating the safety, tolerability & PK profile of Vocabria + Rekambys long-acting injections among 144 adolescents
- Study showed virological suppression (plasma HIV-1 RNA value <50c/mL) in 96.5% (139/144) at wk.24. Additionally, 99% (139/141) preferred long-acting injections over daily oral meds
Ref: GSK | Image: ViiV Healthcare
Related News:- GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
